Literature DB >> 8962720

Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor.

A Yoshida1, B Anand-Apte, B R Zetter.   

Abstract

Neovascularization is a feature of a variety of pathological processes. We compared the characteristics of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) on migration and proliferation of human umbilical vein endothelium (HUVEC). Both VEGF and bFGF induced endothelial cell migration at similar concentrations (1/2 max. VEGF = approximately 1.0 ng/ml, bFGF = approximately 5.0 ng/ml). However, VEGF-stimulated migration was two-fold greater than bFGF at 1 and 10 ng/ml (p < 0.05). In contrast, bFGF induced proliferation four-fold more effectively than VEGF (1/2 max. 1 ng/ml and 1.4 ng/ml respectively). Checkerboard migration assays for bFGF showed a predominantly chemokinetic pattern, whereas VEGF was predominantly chemotactic. VEGF and bFGF were not synergistic in monolayer proliferation and migration assays. Three angiogenesis inhibitors, alpha-interferon, TNP-470, and platelet factor-4, inhibited VEGF and bFGF induced cell migration. These results indicate that VEGF and bFGF are chemoattractants that stimulate endothelial migration by different mechanisms and that both can be inhibited by known angiogenesis inhibitors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8962720     DOI: 10.3109/08977199609034566

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  57 in total

1.  Differential mitogenic responses of human macrovascular and microvascular endothelial cells to cytokines underline their phenotypic heterogeneity.

Authors:  I Lang; C Hoffmann; H Olip; M A Pabst; T Hahn; G Dohr; G Desoye
Journal:  Cell Prolif       Date:  2001-06       Impact factor: 6.831

2.  Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation.

Authors:  K Elenius; S Paul; G Allison; J Sun; M Klagsbrun
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

3.  A cell-based model exhibiting branching and anastomosis during tumor-induced angiogenesis.

Authors:  Amy L Bauer; Trachette L Jackson; Yi Jiang
Journal:  Biophys J       Date:  2007-02-02       Impact factor: 4.033

4.  Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis.

Authors:  Wei Yan; Brooke Bentley; Rong Shao
Journal:  Mol Biol Cell       Date:  2008-03-19       Impact factor: 4.138

5.  Embryonic vasculogenesis and hematopoietic specification.

Authors:  Lauren C Goldie; Melissa K Nix; Karen K Hirschi
Journal:  Organogenesis       Date:  2008-10       Impact factor: 2.500

6.  A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells.

Authors:  J E De Larco; B R Wuertz; K A Rosner; S A Erickson; D E Gamache; J C Manivel; L T Furcht
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

Review 7.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

8.  Antitumor effect of TNP-470 is not associated to decrease of angiogenesis in an experimental malignant neuroectodermic tumor.

Authors:  C Morales; M Zurita; J Vaquero
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

9.  Expression of fibroblast growth factor binding protein in head and neck cancer.

Authors:  Weimin Li; Chuan Wang; Steven K Juhn; Frank G Ondrey; Jizhen Lin
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2009-09

10.  Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Rac1 pathway.

Authors:  S Kamura; Y Matsumoto; J-I Fukushi; T Fujiwara; K Iida; Y Okada; Y Iwamoto
Journal:  Br J Cancer       Date:  2010-07-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.